Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion—a placebo-controlled study in healthy volunteers

Authors: Müller¹; Göksu¹; Fuchs²; Schlüter²; Simon³

Source: Alimentary Pharmacology & Therapeutics, Volume 14, Number 9, September 2000 , pp. 1225-1229(5)

Buy & download fulltext article:

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

Background:

The new tablet formulation of omeprazole (Losec MUPS), is thought to have a stronger acid inhibition than the previously marketed capsules. Methods:

The effects of the proton pump inhibitors lansoprazole and omeprazole tablets on pentagastrin-stimulated acid secretion were compared in Helicobacter pylori-negative healthy male volunteers (n=12). The study was placebo-controlled, crossover matched and double-blind for lansoprazole (Agopton) and placebo, and single-blind for omeprazole tablets. Gastric acid response to sub-maximal pentagastrin-stimulation (0.6 μg · h/kg b.w.) was determined from 12.5 to 14.5 h after the first and second dose of the test drugs. Results:

Lansoprazole 15 mg and 30 mg as well as omeprazole 20 mg tablets caused a marked decrease in gastric acid secretion, showing equipotency for 15 mg lansoprazole and 20 mg omeprazole tablets. Their efficacy, however, was lower than 30 mg lansoprazole. In addition, the inter-individual variation after omeprazole tablets was higher than following lansoprazole. Neither 7.5 mg lansoprazole nor 10 mg omeprazole tablets were clearly different from placebo on the first 2 days.

The drugs were well-tolerated. No clinically relevant influence was found on either laboratory screen or cardiovascular parameters. Conclusion:

Lansoprazole 15-30 mg shows a stronger acid inhibition and a lower inter-individual variability than the new omeprazole 20 mg tablets on days 1 and 2 of dosing.

Document Type: Research article

DOI: http://dx.doi.org/10.1046/j.1365-2036.2000.00823.x

Affiliations: 1: Krankenhaus Salem, Heidelberg, Germany, 2: TAKEDA Pharma GmbH, Aachen, Germany, 3: Kreiskrankenhaus Schwetzingen, Schwetzingen, Germany

Publication date: 2000-09-01

Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion—a placebo-controlled study in healthy volunteers

Buy & download fulltext article:

Tools

Key

Text size:

Useful pages